Changes in Abdominal Adiposity and Associations with Metabolic Health Markers Following Tirzepatide in Japanese Participants with Obesity Disease: Results from the SURMOUNT-J Study
Authors' conclusion
Tirzepatide-induced reductions in body weight and VAT were associated with improvements in metabolic markers and glucose metabolism. Strong associations between anthropometric measures and VAT support their use as surrogate markers of visceral adiposity in Japanese patients with obesity disease.
Study context
- Population
- Japanese adults with obesity disease without diabetesrandomized 1:1:1
- Participants
- 225 adults
- Comparison
- Tirzepatide 10 or 15 mg vs placebo, plus lifestyle modification
- Tirzepatide 10 mgn = 73
- Tirzepatide 15 mgn = 77
- Placebon = 75reference
Methodological detailsprespecified and post hoc analyses
- Prespecified and post hoc analyses
Primary result
As reported in the abstract
Metabolic markers, mean change from baseline · week 72
- High molecular weight adiponectin, mean change: tirzepatide 10 mg / 15 mg vs placebo
- 78.9% and 88.4% vs0.9%
- Leptin: tirzepatide 10 mg / 15 mg vs placebo
- −57.3% and −63.1% vs-8.4%
- High-sensitivity C-reactive protein: tirzepatide 10 mg / 15 mg vs placebo
- −55.1% and −65.3% vs-17.7%
- Procollagen III: tirzepatide 10 mg / 15 mg vs placebo
- −21.3% and −24.8% vs-3.8%
- Cytokeratin-18: tirzepatide 10 mg / 15 mg vs placebo
- −59.8% and −62.0% vs-32.8%
- All of the above vs placebo
- P < .001
Further findings
Correlations of weight loss with abdominal adiposity (post hoc) · week 72
- Weight loss vs VAT reduction, across groups
- r = 0.722-0.837
- VAT reductions vs waist measures
- r = 0.837
- Weight and VAT reductions vs reductions in glucose, insulin and C-peptide AUC
- r = 0.378-0.656
- Weight loss correlated linearly with reductions in adiposity
- Post hoc analyses
Original publication
Changes in Abdominal Adiposity and Associations with Metabolic Health Markers Following Tirzepatide in Japanese Participants with Obesity Disease: Results from the SURMOUNT-J Study. Endocr Pract. Published 19 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →